Top Markets
#1 Derive Derive +31.51%
#2 Cross Cross +16.09%
#3 Glidr Glidr +10.10%
#4 Gama Token Gama Token +9.09%
#5 Palladium Network Palladium Network +5.01%
#6 Based Based +4.88%
#7 TDCCP TDCCP +4.76%
#8 Akedo Akedo +4.66%
#9 龙虾 (Lobster) 龙虾 (Lobster) +4.64%
#10 LEO Token LEO Token +4.36%
Coin of the day
Derive Derive
設定
言語
日本
通貨
USD
テーマ
Guard Therapeutics International AB (publ) Guard Therapeutics International AB (publ)

Guard Therapeutics International AB (publ)

GUARD
株式のランク #36113
Guard Therapeutics International AB (publ) is a Swedish pharmaceutical company... Guard Therapeutics International AB (publ) is a Swedish pharmaceutical company dedicated to the research, development, and commercialization of therapeutic solutions for the diagnosis and management of acute kidney injuries. A key offering is ROSGard, a biological drug candidate designed to prevent kidney impairment through the protection, purification, and restoration of affected cells and tissues. Founded in 2008, the company operated as A1M Pharma AB (publ) until its renaming to Guard Therapeutics International AB (publ) in October 2019. Its headquarters are located in Stockholm, Sweden.
株価
$0.14966934
最終同期: 2026-08-14
時価総額
$3.02M
変化（1日）
3.72%
変化（1年）
-93.70%
国
SE
取引 Guard Therapeutics International AB (publ) (GUARD)

カテゴリー

Healthcare
Guard Therapeutics International AB (publ)（GUARD）の利益
2026 時点の利益 TTM: 0
Guard Therapeutics International AB (publ) の最新の財務報告によると、同社の現在の利益は 0 です。2026 年には 0 の利益を上げ、これは 2026 年の利益 0 と 同等 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Guard Therapeutics International AB (publ) の利益の推移（2026 〜 2026）
各年末の利益
年 利益 変化
提供された日付のデータは十分ではありません。
同業他社の利益
企業 利益 利益の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE